scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.THROMRES.2015.08.010 |
P698 | PubMed publication ID | 26440977 |
P50 | author | Angelika Geroldinger | Q64007617 |
Cihan Ay | Q66126625 | ||
Heinz-Josef Lenz | Q89668545 | ||
Gabriela Kornek | Q110415456 | ||
P2093 | author name string | Ingrid Pabinger | |
Alexandra Kaider | |||
Christoph C Zielinski | |||
Alexandra Schuler | |||
Werner Scheithauer | |||
Gerald W Prager | |||
Clemens Pausz | |||
Daniela Bianconi | |||
P2860 | cites work | Coagulation and cancer: biological and clinical aspects | Q38070918 |
Insights in microRNAs biology | Q38112762 | ||
Biomarkers for prediction of venous thromboembolism in cancer | Q38125998 | ||
Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). | Q38214965 | ||
Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. | Q39954054 | ||
Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). | Q41456560 | ||
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer | Q41714515 | ||
CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling. | Q46066210 | ||
Prediction of venous thromboembolism in cancer patients. | Q51662626 | ||
A solution to the problem of monotone likelihood in Cox regression. | Q52929496 | ||
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). | Q53472586 | ||
Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). | Q54489258 | ||
A note on quantifying follow-up in studies of failure time | Q71721709 | ||
Venous thrombosis in patients with solid tumors: determination of frequency and characteristics | Q74090799 | ||
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy | Q79825413 | ||
Incidence of venous thromboembolism and its effect on survival among patients with common cancers | Q82676244 | ||
Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival | Q82676944 | ||
Thrombosis risk and survival in cancer patients with elevated C-reactive protein | Q85100868 | ||
Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study | Q87372024 | ||
An integrated map of genetic variation from 1,092 human genomes | Q22122153 | ||
Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects | Q24657848 | ||
Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis | Q27005043 | ||
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial | Q28185738 | ||
Kindlin-2 controls bidirectional signaling of integrins | Q28507652 | ||
A note on including time-dependent covariate in regression model for competing risks data | Q31031448 | ||
Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins | Q33483955 | ||
The final steps of integrin activation: the end game | Q34106011 | ||
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines | Q34215315 | ||
Function and interactions of integrins | Q34381197 | ||
Genetic variation of ITGB3 is associated with asthma in Chinese Han children | Q34602730 | ||
Signaling during platelet adhesion and activation | Q34895427 | ||
Integrin targeted therapeutics | Q34912684 | ||
MicroRNA function: multiple mechanisms for a tiny RNA? | Q36325449 | ||
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. | Q36984787 | ||
Antithrombotic effects of targeting alphaIIbbeta3 signaling in platelets | Q37157980 | ||
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
Roles of integrins in tumor angiogenesis and lymphangiogenesis. | Q37354204 | ||
Cancer, clots and consensus: new understanding of an old problem. | Q37393386 | ||
Assessing risk of venous thromboembolism in the patient with cancer. | Q37393394 | ||
Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis | Q37404403 | ||
The role of β3-integrins in tumor angiogenesis: context is everything | Q37874786 | ||
Angiogenesis in cancer. Basic mechanisms and therapeutic advances | Q37916313 | ||
Endothelial progenitor cells and integrins: adhesive needs | Q37992761 | ||
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis | Q38042484 | ||
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. | Q38059698 | ||
Cancer-associated thrombosis: updates and controversies | Q38066930 | ||
P433 | issue | 5 | |
P921 | main subject | colorectal cancer | Q188874 |
venous thromboembolism | Q9397786 | ||
colorectal carcinoma | Q25493920 | ||
P304 | page(s) | 865-869 | |
P577 | publication date | 2015-08-28 | |
P1433 | published in | Thrombosis Research | Q15758741 |
P1476 | title | Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients | |
P478 | volume | 136 |
Q57824763 | Cancer-associated thrombosis: The search for the holy grail continues |
Q88979484 | Common rs5918 (PlA1/A2) polymorphism in the ITGB3 gene and risk of coronary artery disease |
Q55297156 | Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma. |
Q98183400 | Genes and proteins associated with the risk for cancer-associated thrombosis |
Q28066805 | Integrins in the Spotlight of Cancer |
Q98778926 | Roles of microRNA-186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus |
Q53142866 | Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. |
Search more.